Mechanism of Amphotericin B-Induced Hypokalemia
Pathophysiological Mechanisms
- Amphotericin B causes selective distal tubular epithelial toxicity, leading to potassium wasting through the distal tubules, as reported by the MMWR Recommendations and Reports 1, 2
- The drug binds to cholesterol in mammalian cell membranes, leading to end-organ dysfunction, particularly in the kidneys, according to Clinical Infectious Diseases 3
- The nephrotoxicity manifests as both glomerular damage (causing azotemia) and tubular damage (causing hypokalemia), as stated by MMWR Recommendations and Reports 1
Clinical Manifestations and Progression
- Hypokalemia occurs in up to 80% of patients receiving conventional amphotericin B treatment, as reported by Clinical Infectious Diseases 4
Risk Factors and Aggravating Conditions
- Concomitant use of other nephrotoxic medications increases the risk and severity of hypokalemia, according to MMWR Recommendations and Reports and Clinical Infectious Diseases 1, 4
- Higher doses of amphotericin B (>1 mg/kg) are associated with more severe electrolyte abnormalities, as stated by MMWR Recommendations and Reports 1
Prevention and Management Strategies
- Hydration with 0.9% saline intravenously 30 minutes before amphotericin B infusion can ameliorate nephrotoxicity and reduce hypokalemia, as recommended by MMWR Recommendations and Reports 1
- Regular monitoring of serum electrolytes (particularly potassium and magnesium) is essential during therapy, according to Clinical Infectious Diseases 3, 5
- Lipid formulations of amphotericin B (liposomal amphotericin B, amphotericin B lipid complex) are generally less nephrotoxic than conventional amphotericin B deoxycholate, as reported by Clinical Infectious Diseases 3, 5
Clinical Implications
- Hypokalemia can lead to muscle weakness, cardiac arrhythmias, and increased risk of digitalis toxicity, as stated by Clinical Infectious Diseases 4
- Monitoring should include baseline and frequent (once or twice weekly) serum chemistry values, according to Clinical Infectious Diseases 5
- Electrolyte supplementation, increased intervals between doses, or drug holidays may be required in severe cases, as recommended by Clinical Infectious Diseases 5
- In patients with azotemia or hyperkalemia, longer infusion times (3-6 hours) are recommended to reduce toxicity, as stated by MMWR Recommendations and Reports 1
Amphotericin B-Induced Renal Tubular Acidosis
Mechanism and Clinical Manifestations
- Amphotericin B causes selective distal tubular epithelial toxicity, leading to renal tubular acidosis through direct damage to the renal tubules, resulting in end-organ dysfunction, particularly affecting kidney tubular function 6, 7
- The acidosis is accompanied by electrolyte abnormalities including hypokalemia (in up to 80% of patients), urinary potassium and magnesium wasting 6, 7
Formulation-Specific Considerations
- Amphotericin B deoxycholate has the highest risk of causing renal tubular acidosis and should be reserved for resource-limited settings where alternatives are unavailable 6
- Lipid formulations (liposomal amphotericin B, amphotericin B lipid complex) have considerably less nephrotoxicity, including reduced risk of acidosis, compared to the deoxycholate formulation 6, 7, 8
Risk Factors for Severity
- Pre-existing renal impairment, diabetes mellitus, and underlying renal disease increase risk 9
Prevention and Monitoring Strategies
- Regular monitoring of serum electrolytes (particularly potassium, magnesium, and bicarbonate) is essential during therapy 6
- Volume expansion with a salt load immediately prior to dosing, and monitoring with repletion of potassium and magnesium as needed, are warranted 6